Novel human suicide gene for oncolytic virotherapy and safety switch in cell based therapies


28 Juillet 2015

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+


Biology / Medical


  • Based on a novel approach of gene evolution (Retrovolution) unprecedented highly potent hdCK mutants were isolated
  • hdcK M36 mutant results in only 4 mutations compared to the WT hdCK but exhibits, on Gemcitabine resistant cells (Messa-10K) a 900-fold decrease in IC50 with Gemcitabine and 10 000-fold decrease with Cytarabine


  • A first mutant G12, already showed promising results (published). By evolving the G12 gene, another even more potent mutant (M36) was selected and tested on Messa 10K cells
  • M36 induces unprecedented 900 fold decreasein IC50 for Gemcitabine and 10000 fold for cYTARABINE
  • Mutation results in loss of affinity for the natural substrate


  • Suicide Gene therapy for anti-cancer treatment
  • Safety switch for cellular therapy approaches in cancer and regenerative medicine (transplantation, CARs or TCRs, iPSC based therapies)


  • Inducing cell death in presence of low doses of cytotoxic dru g
  • Currently clinically employed anticancer drug
  • Countering the unwanted side-effects and improving the effectiveness
  • Overcoming potential resistance arising during treatment
  • Human enzyme mutant : Absence of Immunogenicity
Download the offer Download the offer